Neurocrine Biosciences Reiterates FY24 INGREZZA Net Product Sales Outlook In The Band Of 2.10B-$2.20B
Portfolio Pulse from Benzinga Newsdesk
Neurocrine Biosciences has reaffirmed its fiscal year 2024 net product sales forecast for INGREZZA, projecting sales to be in the range of $2.10 billion to $2.20 billion.
May 01, 2024 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neurocrine Biosciences reiterates its FY24 sales outlook for INGREZZA, expecting revenues between $2.10B and $2.20B.
Reiterating a strong sales outlook for a key product like INGREZZA signals confidence in the product's market performance and potential for growth. This reaffirmation could positively influence investor sentiment and potentially lead to an uptick in NBIX's stock price in the short term, as it underscores the company's financial health and growth prospects.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100